Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
Fiche publication
Date publication
janvier 2017
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A,
Lien Pubmed
Résumé
Therapeutic options are limited in secondary progressive multiple sclerosis (SPMS). Open-label studies suggested efficacy of monthly IV cyclophosphamide (CPM) without induction for delaying progression but no randomized trial was conducted so far.
Mots clés
Adolescent, Adult, Aged, Anti-Inflammatory Agents, therapeutic use, Cyclophosphamide, therapeutic use, Disabled Persons, Disease Progression, Double-Blind Method, Female, France, Humans, Immunosuppressive Agents, therapeutic use, Male, Methylprednisolone, therapeutic use, Middle Aged, Multiple Sclerosis, Chronic Progressive, drug therapy, Proportional Hazards Models, Severity of Illness Index, Young Adult
Référence
PLoS ONE. 2017 ;12(1):e0168834